Tuning p53-Dependent Cell Fate for Radioprotection/Mitigation

This project aims to develop a small molecule that “tunes” p53‑dependent cell fate decisions after radiation exposure to favor tissue preservation rather than cell death. By modulating p53 signaling dynamics, the therapy is designed to prevent or mitigate the lethal tissue injury that underlies acute radiation syndrome in otherwise healthy individuals. Over two years, the team will generate a translational package that includes pharmacokinetics, pharmacodynamics, specificity, and early safety data, along with functional studies in human and mouse hematopoietic systems and human intestinal organoids. These efforts will be complemented by in vivo efficacy studies in mouse models of radiation injury to support advancement as a single‑agent medical countermeasure suitable for stockpiling and rapid deployment.